Cathay Biotech Inc (688065) - Total Assets
Based on the latest financial reports, Cathay Biotech Inc (688065) holds total assets worth CN¥24.61 Billion CNY (≈ $3.60 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cathay Biotech Inc - Total Assets Trend (2016–2025)
This chart illustrates how Cathay Biotech Inc's total assets have evolved over time, based on quarterly financial data. Also see 688065 market cap overview for the company's overall valuation and market capitalisation.
Cathay Biotech Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Cathay Biotech Inc's total assets of CN¥24.61 Billion consist of 49.1% current assets and 50.9% non-current assets. Review Cathay Biotech Inc (688065) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 38.7% |
| Accounts Receivable | CN¥297.50 Million | 1.3% |
| Inventory | CN¥1.44 Billion | 6.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥728.50 Million | 3.1% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Cathay Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 688065 stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cathay Biotech Inc's current assets represent 49.1% of total assets in 2025, an increase from 47.8% in 2016.
- Cash Position: Cash and equivalents constituted 38.7% of total assets in 2025, up from 21.1% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 1.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 6.0% of total assets.
Cathay Biotech Inc Competitors by Total Assets
Key competitors of Cathay Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Zhejiang Sanmei Chemical Industry Co Ltd
SHG:603379
|
China | CN¥9.36 Billion |
|
Sichuan Hebang Biotechnology Co Ltd
SHG:603077
|
China | CN¥29.64 Billion |
|
Shaanxi Lighte Optoelectronics Material Co. Ltd. A
SHG:688150
|
China | CN¥2.28 Billion |
|
Zhejiang Yongtai Technology Co Ltd
SHE:002326
|
China | CN¥11.10 Billion |
|
Robertet SA
PA:RBT
|
France | €1.00 Billion |
|
HeBei Jinniu Chemical Industry Co Ltd
SHG:600722
|
China | CN¥1.49 Billion |
|
Inner Mongolia Lantai Industrial Co Ltd
SHG:600328
|
China | CN¥25.24 Billion |
|
Shaanxi Heimao Coking Co Ltd
SHG:601015
|
China | CN¥19.72 Billion |
Cathay Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.25 | 6.40 | 11.72 |
| Quick Ratio | 4.63 | 5.78 | 10.76 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥9.68 Billion | CN¥10.14 Billion | CN¥10.04 Billion |
Cathay Biotech Inc - Advanced Valuation Insights
This section examines the relationship between Cathay Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.61 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | 25.6% |
| Total Assets | CN¥23.88 Billion |
| Market Capitalization | $4.05 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Cathay Biotech Inc's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Cathay Biotech Inc's assets grew by 25.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Cathay Biotech Inc (2016–2025)
The table below shows the annual total assets of Cathay Biotech Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥23.88 Billion ≈ $3.49 Billion |
+25.55% |
| 2024-12-31 | CN¥19.02 Billion ≈ $2.78 Billion |
+1.00% |
| 2023-12-31 | CN¥18.83 Billion ≈ $2.76 Billion |
+5.64% |
| 2022-12-31 | CN¥17.83 Billion ≈ $2.61 Billion |
+10.06% |
| 2021-12-31 | CN¥16.20 Billion ≈ $2.37 Billion |
+33.48% |
| 2020-12-31 | CN¥12.14 Billion ≈ $1.78 Billion |
+102.87% |
| 2019-12-31 | CN¥5.98 Billion ≈ $875.32 Million |
+23.60% |
| 2018-12-31 | CN¥4.84 Billion ≈ $708.19 Million |
+54.45% |
| 2017-12-31 | CN¥3.13 Billion ≈ $458.51 Million |
+88.98% |
| 2016-12-31 | CN¥1.66 Billion ≈ $242.62 Million |
-- |
About Cathay Biotech Inc
Cathay Biotech Inc., together with its subsidiaries, engages in the research, development, production, and sale of bio-based materials in China and internationally. The company offers biological long-chain diacids, including sebacic acid and octadecanedioic acid; bio-based polyamides; and bio-based pentamethylene diamine under the TERRYL and ECOPENT brands. It also provides digital solutions for … Read more